ATE364177T1 - Kombinationen von markern zum nachweis von typ 1 und 2 diabetes - Google Patents
Kombinationen von markern zum nachweis von typ 1 und 2 diabetesInfo
- Publication number
- ATE364177T1 ATE364177T1 AT05014521T AT05014521T ATE364177T1 AT E364177 T1 ATE364177 T1 AT E364177T1 AT 05014521 T AT05014521 T AT 05014521T AT 05014521 T AT05014521 T AT 05014521T AT E364177 T1 ATE364177 T1 AT E364177T1
- Authority
- AT
- Austria
- Prior art keywords
- markers
- risk
- cardiovascular complication
- suffering
- diabetes
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 abstract 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 abstract 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 abstract 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102400001263 NT-proBNP Human genes 0.000 abstract 1
- 108020001621 Natriuretic Peptide Proteins 0.000 abstract 1
- 102000004571 Natriuretic peptide Human genes 0.000 abstract 1
- 102100035194 Placenta growth factor Human genes 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000000692 natriuretic peptide Substances 0.000 abstract 1
- 230000010118 platelet activation Effects 0.000 abstract 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 abstract 1
- 238000013517 stratification Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04015936 | 2004-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE364177T1 true ATE364177T1 (de) | 2007-06-15 |
Family
ID=35589257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05014521T ATE364177T1 (de) | 2004-07-07 | 2005-07-05 | Kombinationen von markern zum nachweis von typ 1 und 2 diabetes |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060019315A1 (de) |
| JP (1) | JP4488968B2 (de) |
| AT (1) | ATE364177T1 (de) |
| CA (1) | CA2511649A1 (de) |
| DE (1) | DE602005001299T2 (de) |
| ES (1) | ES2288718T3 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1882945A1 (de) * | 2006-07-28 | 2008-01-30 | F.Hoffmann-La Roche Ag | Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot |
| ATE476665T1 (de) * | 2006-09-20 | 2010-08-15 | Hoffmann La Roche | Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion |
| CA2667119C (en) * | 2006-10-18 | 2016-04-12 | Axela Inc. | Measuring multiple analytes over a broad range of concentrations using optical diffraction |
| WO2009004443A2 (en) * | 2007-07-04 | 2009-01-08 | Medizinische Universität Wien | Compositions for the detection of gene expression in diabetic microangiopathy |
| EP2037277A1 (de) * | 2007-09-11 | 2009-03-18 | F. Hoffmann-La Roche AG | Verfahren zum Testen der funktionalen Integrität und der Qualität einer Blutplättchenprobe |
| EP2090891A1 (de) * | 2008-02-13 | 2009-08-19 | F.Hoffmann-La Roche Ag | Mittel und Verfahren zur Bestimmung der atherosklerotischen Last unter Verwendung von Biomarker-PLGF |
| EP2304438A1 (de) * | 2008-06-13 | 2011-04-06 | F. Hoffmann-La Roche AG | Beurteilung von komplikationen bei patienten mit typ-1-diabetes |
| WO2009150249A1 (en) * | 2008-06-13 | 2009-12-17 | Roche Diagnostics Gmbh | Nt-probnp as prognostic indicator for the development of end stage renal disease in diabetes mellitus |
| EP2529235B1 (de) * | 2010-01-29 | 2019-03-06 | Metanomics GmbH | Mittel und verfahren zur diagnostizierung von herzinsuffizienz bei einer person |
| US20140324460A1 (en) * | 2012-09-26 | 2014-10-30 | Health Diagnostic Laboratory, Inc. | Method for determining and managing total cardiodiabetes risk |
| EP2843415B1 (de) * | 2013-08-30 | 2020-04-01 | LURIC Datenbank GbR | Verfahren für die Beurteilung des kardiovaskulären Risikos bei Diabetikern |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| FR3109999B1 (fr) * | 2020-05-05 | 2024-06-14 | Francais Du Sang Ets | Methode de detection de l’activation plaquettaire liee a l’inflammation |
| JP7440093B2 (ja) * | 2021-03-15 | 2024-02-28 | 株式会社カルナヘルスサポート | 末期腎不全発症予測方法 |
| CN114609395B (zh) * | 2022-04-25 | 2024-03-29 | 李玉凤 | 一种预测或诊断糖尿病或糖尿病肾病患者中的早期动脉粥样硬化的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100497393C (zh) * | 2003-05-12 | 2009-06-10 | 霍夫曼-拉罗奇有限公司 | 用结合脑钠尿肽前体分子氨基酸41-46的单克隆抗体检测脑钠尿肽前体分子的方法 |
| US20060257558A1 (en) * | 2003-10-31 | 2006-11-16 | Hiroshi Nomura | Plasma polymerization of atomically modified surfaces |
| SI1882946T1 (sl) * | 2003-12-23 | 2010-06-30 | Hoffmann La Roche | Postopek za ugotavljanje revmatoidnega artritisa z merjenjem anti CCP in interlevkina |
-
2005
- 2005-07-05 AT AT05014521T patent/ATE364177T1/de not_active IP Right Cessation
- 2005-07-05 ES ES05014521T patent/ES2288718T3/es not_active Expired - Lifetime
- 2005-07-05 DE DE602005001299T patent/DE602005001299T2/de not_active Expired - Lifetime
- 2005-07-06 US US11/175,870 patent/US20060019315A1/en not_active Abandoned
- 2005-07-06 CA CA002511649A patent/CA2511649A1/en not_active Abandoned
- 2005-07-06 JP JP2005197234A patent/JP4488968B2/ja not_active Expired - Fee Related
-
2006
- 2006-03-09 US US11/371,871 patent/US20070015208A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005001299T2 (de) | 2008-02-07 |
| JP2006030182A (ja) | 2006-02-02 |
| CA2511649A1 (en) | 2006-01-07 |
| US20070015208A1 (en) | 2007-01-18 |
| JP4488968B2 (ja) | 2010-06-23 |
| DE602005001299D1 (de) | 2007-07-19 |
| US20060019315A1 (en) | 2006-01-26 |
| ES2288718T3 (es) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE373827T1 (de) | Kombination von markern für diabetes typ 1 und 2 | |
| ATE364177T1 (de) | Kombinationen von markern zum nachweis von typ 1 und 2 diabetes | |
| ATE469353T1 (de) | Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen | |
| ATE403157T1 (de) | Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung | |
| CN101568833B (zh) | 使用MR-proADM的糖尿病诊断和风险分级 | |
| JP2010513879A5 (de) | ||
| RU2014118584A (ru) | Композиции и способы лечения сердечной недостаточности | |
| JP2008046129A5 (de) | ||
| WO2004046194A3 (en) | Polyclonal-monoclonal elisa assay for detecting n-terminus probnp | |
| CN101636657A (zh) | 借助于利尿肽对nyhai级患者进行心功能不全的诊断和危险分层 | |
| CN101646945A (zh) | 利用CT-proET-1与NT-proBNP的组合进行急性冠状动脉综合征的诊断和风险分层 | |
| RU2014145259A (ru) | Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности | |
| CA2567738A1 (en) | The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication | |
| PT1849009E (pt) | Utilização de hormonas cardíacas para avaliar um risco cardiovascular em relação à administração de fármacos anti-inflamatórios | |
| JP2011523044A5 (de) | ||
| RU2012115125A (ru) | Мультимаркерная панель для гипертрофии левого желудочка | |
| Ma et al. | Plasma pituitary adenylate cyclase-activating polypeptide concentrations and mortality after acute spontaneous basal ganglia hemorrhage | |
| WO2011054829A1 (en) | NT-pro ANP AND SFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS | |
| JP2010511877A5 (de) | ||
| JP2012516436A5 (de) | ||
| Jelic et al. | Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure | |
| DE602006015964D1 (de) | Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion | |
| Banfi et al. | N-terminal proB-type natriuretic peptide (NT-proBNP) concentrations in elite rugby players at rest and after active and passive recovery following strenuous training sessions | |
| CN203858247U (zh) | 一种n-端脑钠肽前体检测试纸条 | |
| RU2015133019A (ru) | Способ прогнозирования риска развития рака или диагностирования рака у индивидуума |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1615035 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |